Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Pfizer Acquires NextWave | Contract Pharma

What are you searching for?

Sign in
Breaking News

Pfizer Acquires NextWave

Gains rights to liquid ADHD treatment

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Pfizer has acquired NextWave Pharmaceuticals, a privately held specialty pharmaceutical company focused on the development and commercialization of products for the treatment of attention deficit hyperactivity disorder (ADHD).
 
Pfizer now has exclusive North American commercialization rights to Quillivant XR (methylphenidate hydrochloride) for extended-release oral suspension, the first once-daily liquid medication approved in the U.S. to treat ADHD. Quillivant XR was approved by the FDA in September and is expected to be available in January 2013. Financial terms of the acquisitions were not disclosed

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters